Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults

• Main Authors: Isabel Leroux-Roels (Author), Geert Leroux-Roels (Author), Georgi Shukarev (Author), Hanneke Schuitemaker (Author), Conor Cahill (Author), Richard de Rooij (Author), Martin Struijs (Author), Hester van Zeeburg (Author), Jeanne-Marie Jacquet (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

This first-in-human study (NCT03032588), conducted in Belgium, evaluated a new inactivated poliovirus vaccines (IPV) candidate based on Sabin poliovirus strains grown on the high-yield PER.C6® cell line. Healthy adults (N = 32) were randomized (1:1) to receive a single dose of PER.C6-based Sabin-IPV...